Acumen Pharmaceuticals, Inc. (ABOS) AI Dilution Summary

Estimated cash was $78,604,000 as of 2026-09-30, against estimated monthly burn of $8,884,333. The company has an active ATM program with BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated and BTIG, LLC as sales agents. The program is authorised to $50,000,000, and $12,200,000 has been sold to date.